Our Hyperloop™ Platform combines cutting-edge structure-based drug discovery with AI-powered computational methods and experimental validation to identify and develop small molecule therapeutics.
Focusing initially on GPCRs, our pipeline blends scientific innovation with patient-centric precision to develop next-generation treatments for cardiometabolic diseases.
We are a passionate team of scientists and innovators dedicated to transforming how medicines are discovered.
Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to rapidly unlock the most challenging G protein-coupled receptors (GPCRs), today announced a collaboration with Eli Lilly and Company (“Lilly”) to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity.
Superluminal is eligible to receive up to $1.3 billion, which includes upfront and near-term payments, an equity investment, development and commercial milestones, as well as tiered royalties on net sales.